A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder
Open accessThe DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
To date, no large-scale, controlled trial comparing a serotonin-norepinephrine reuptake inhibitor and selective serotonin reuptake inhibitor with placebo for the treatment of panic disorder has been reported. This double-blind study compares the efficacy of venlafaxine extended-release (ER) and paroxetine with placebo. A total of 664 nondepressed adult outpatients who met DSM-IV criteria for panic disorder (with or without agoraphobia) were randomly assigned to 12 weeks of treatment with placebo or fixed-dose venlafaxine ER (75 mg/day or 150 mg/day), or paroxetine 40 mg/day. The primary measure was the percentage of patients free from full-symptom panic attacks, assessed with the Panic and Anticipatory Anxiety Scale (PAAS). Secondary measures included the Panic Disorder Severity Scale, Clinical Global Impressions--Severity (CGI-S) and--Improvement (CGI-I) scales; response (CGI-I rating of very much improved or much improved), remission (CGI-S rating of not at all ill or borderline ill and no PAAS full-symptom panic attacks); and measures of depression, anxiety, phobic fear and avoidance, anticipatory anxiety, functioning, and quality of life. Intent-to-treat, last observation carried forward analysis showed that mean improvement on most measures was greater with venlafaxine ER or paroxetine than with placebo. No significant differences were observed between active treatment groups. Panic-free rates at end point with active treatment ranged from 54% to 61%, compared with 35% for placebo. Approximately 75% of patients given active treatment were responders, and nearly 45% achieved remission. The placebo response rate was slightly above 55%, with remission near 25%. Adverse events were mild or moderate and similar between active treatment groups. Venlafaxine ER and paroxetine were effective and well tolerated in the treatment of panic disorder.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brief standard self-rating for phobic patients
Marks, I. M., & Mathews, A. M. (1979) · Behaviour Research and Therapy · doi:10.1016/0005-7967(79)90041-x · Cited by 1,801
Multicenter Collaborative Panic Disorder Severity Scale
Shear, M. K., Brown, T. A., Barlow, D. H., Money, R., Sholomskas, D. E., Woods, S. W., Gorman, J. M., & Papp, L. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1571 · Cited by 1,001 · cited 1×
“Secondary outcome measures included changes from baseline in the Panic Disorder Severity Scale [PDSS; Shear et al., 1997] total score, panic attack frequency, and anticipatory anxiety as measured by the PAAS, phobic fear and avoidance as assessed with the Phobia Scale [Marks and Mathews, 1979;…”
MethodBarlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Paroxetine in the Treatment of Panic Disorder a Randomised, Double-Blind, Placebo-Controlled Study
Oehrberg, S., Christiansen, P. E., Behnke, K., Borup, A. L., Severin, B., Soegaard, J., Calberg, H., Judge, R., Ohrstrom, J. K., & Manniche, P. M. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.3.374 · Cited by 261
Allgulander, C., Hackett, D., & Salinas, E. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.1.15 · Cited by 175 · cited 2×
“…(IR) and ER formulations for the treatment of major depression, [Smith et al., 2002; Thase et al., 2001], generalized anxiety disorder [GAD; Allgulander et al., 2001; Gelenberg et al., 2000; Rickels et al., 2000], and social anxiety disorder [Allgulander et al., 2004; Liebowitz et al.,…”
BackgroundSelf-citationLong‐term evaluation of paroxetine, clomipramine and placebo in panic disorder
Lecrubier, Y., Judge, R., & The Collaborative Paroxetine Panic Study Investigators (1997) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.1997.tb00389.x · Cited by 139
Sertraline treatment of panic disorder: results of a long-term study
Rapaport, M. H., Wolkow, R., Rubin, A., Hackett, E., Pollack, M., & Ota, K. Y. (2001) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2001.00263.x · Cited by 79
Self-citationMichelson, D., Allgulander, C., Dantendorfer, K., Knezevic, A., Maierhofer, D., Micev, V., Paunovic, V. R., Timotijevic, I., Sarkar, N., Skoglund, L., et al. (2001) · British Journal of Psychiatry · doi:10.1192/bjp.179.6.514 · Cited by 62 · cited 1×
“Randomized clinical trials have demonstrated the effectiveness of fluoxetine [Michelson et al., 1998, 1999, 2001; Tiller et al., 1999], fluvoxamine [Black et al., 1993; den Boer, 1998; Sharp et al., 1997], paroxetine [Ballenger et al., 1998b; Oehrberg et al., 1995], sertraline [Londborg et al.,…”
Background
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Baldwin, D. S., Anderson, I. M., Nutt, D. J., Allgulander, C., Bandelow, B., den Boer, J. A., Christmas, D. M., Davies, S., Fineberg, N., Lidbetter, N., et al. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114525674 · Cited by 676
“…studies suggest that higher daily doses of some antidepressants [I (PCT)] (paroxetine, fluoxetine: Ballenger et al., 1998; Michelson et al., 1998) but not others [I (PCT)] (citalopram, venlafaxine: Pollack et al., 2007; Wade et al., 1997) may be superior in efficacy to lower doses.”
BackgroundAndrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
Metadata
- Authors
- Pollack, M. H., Lepola, U., Koponen, H., Simon, N. M., Worthington, J. J., Emilien, G., Tzanis, E., Salinas, E., Whitaker, T., & Gao, B.
- Venue
- Depression and Anxiety
- Publisher
- Hindawi Limited
- Published
- 2006
- Volume
- 24
- Issue
- 1
- Pages
- 1-14
- ISSN
- 1091-4269 (ISSN-L)
- 1520-6394
- OpenAlex
- W1996298226
- Cited by
- 102
- References
- 8
- FWCI
- 10.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. https://app.cochat.ai/papers/10.1002/da.20218
- The paper
- Pollack, M. H., Lepola, U., Koponen, H., Simon, N. M., Worthington, J. J., Emilien, G., Tzanis, E., Salinas, E., Whitaker, T., & Gao, B. (2007). A double-blind study of the efficacy of venlafaxine extended-release, paroxetine, and placebo in the treatment of panic disorder. Depression and Anxiety. https://doi.org/10.1002/da.20218
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.